Study of the Effect of SR57667B in Patients With Alzheimer's Disease
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The primary objective is to demonstrate that SR57667B at the dose of 4 mg/day, in comparison
to placebo, decreases the decline in cognitive performance and the global clinical decline
over 1 year in patients with mild to moderate AD.
Secondary objectives are to assess the effect of SR57667B on functional decline and its
safety/tolerability in patients with mild to moderate AD, and to document plasma
concentrations of SR57667 in patients with mild to moderate AD.